December 23rd, 2004

Jacqueline D. Cook
Senior Health physicist
Nuclear Regulatory commission
Region IV
611 Ryan Plaza Drive Suite 400
Arlington Texas 76011-6064

Via Fax:817—860-8263

License # 40-01683-01
Docket # 030-03235
Control # 470298

Dear Ms. Cook:

This is in response to your telephone enquiry followed with a fax dated 12/21/04 pertaining to additional information regarding our renewal application.

- I will confirm that Dr. Wells should be deleted from the license as he is retiring.
- Dr. Dvork should be authorized for 10 CFR 35.400 materials that he is currently authorized on our license.

Dr. Posch should be added to the license effective immediately. I am sending Praire Lakes Health care Systems Inc. License, 40-16775-01 on which Dr. Posch is identified as an authorized user for 10 CFR 35.100, 35.200, 35.300 in vitro studies.

I hope I have provided you with all the information requested by you to proceed with the review process. If you require additional information, please do not hesitate to contact me.

Sincerely,

S. Guru Prasad, Ph.D., DABR
Radiological Physicist
Avera Sacred Heart Hosptal
Yankton SD

Cc: Robin Berke

DEC 2 3 2004

Jacqueline D. Cook
Senior Health physicist
Nuclear Regulatory commission
Region IV
611 Ryan Plaza Drive Suite 400
Arlington Texas 76011-6064

Via fax 817-860-8263

From:
S. Guru Prasad
License # 40-01683-01

No of pages including this one is six

Call 847-570-255 if there any problems with transmission.

847-570-1879 fax
605-668-8153 (fax)
Robin Berke

NRC FORM 374 U.S. NUCLEAR REGULATORY COMMISSION PAGE 1 OF 4 PAGES
Amendment No. 19

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with application dated December 23, 2002
1. Prairie Lakes Health Care Systems, Inc.	3. License number 40-16775-01 is amended in its entirety to read as follows:
2. 400 10th Avenue Northwest P.O. Box 1210 Watertown, South Dakota 57201-6210	4. Expiration date June 30, 2013
	5. Docket No. 030-11624 Reference No.

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 2 curies
D. Any byproduct material permitted by 10 CFR 35.400	D. Sealed Sources (Isotope Products Laboratories Model 67-800 series; AEA Technology Model CDC.T1; Amersham Corporation Model CDC.CY192; Best Medical International, Inc. Model 81-01)	D. 1500 millicuries
E. Sr-90 permitted by 10 CFR 35.400	F. Sealed Source (DuPont Merck Pharmaceutical Co., [formerly New England Nuclear] Model NB-1)	F. 100 millicuries
F. Any byproduct material permitted by 10 CFR 31.11	F. Prepackaged Kits	F. 50 millicuries

9. Authorized use:

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
B. Any imaging and localization study permitted by 10 CFR 35.200.
C. Any therapy procedure permitted by 10 CFR 35.300.
D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
E. For storage only.
F. In vitro studies.

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION	PAGE 2 of 4 PAGES
MATERIALS LICENSE **SUPPLEMENTARY SHEET**	License Number 40-16775-01
	Docket or Reference Number 030-11624
	Amendment No. 19

CONDITIONS

10. Licensed material may be used or stored only the licensee's facilities located at 400 10th Avenue Northwest, Watertown, South Dakota.

11. Radiation Safety Officer for this license is Thomas J. Posch, M.D.

12. Licensed material is only authorized for use by, or under the supervision of:

    A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 35.14.

    B. The following individuals are authorized users for the materials and uses indicated:

Authorized Users	Material and Use
Robert N. Crank, M.D.	35.100; 35.200; 35.300; *In vitro* studies
Zeke L. Hendricks, M.D.	35.100; 35.200; *In vitro* studies
Robert Allen Low, M.D.	35.100; 35.200; *In vitro* studies
Jim Schwaiger, M.D.	35.100; 35.200; 35.300
William K. Bishop, M.D.	35.100; 35.200; 35.300; *In vitro* studies
Thomas J. Posch, M.D.	35.100; 35.200; 35.300; *In vitro* studies
Jeffrey S. Brindle, M.D.	35.300; 35.400

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

14. For sealed sources not associated with 10 CFR Part 35 use, the following conditions apply:

    A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed the intervals specified in the certificate of registration issued by U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State.

    B. Notwithstanding Paragraph A of this Condition, sealed sources designed to primarily emit alpha particles shall be tested for leakage and/or contamination at intervals not to exceed 3 months.

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
40-16775-01

Docket or Reference Number
030-11624

Amendment No. 19

C. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.

D. Sealed sources need not be leak tested if they contain only hydrogen-3; or they contain only a radioactive gas; or the half-life of the isotope is 30 days or less; or they contain not more than 100 microcuries of beta- and/or gamma-emitting material or not more than 10 microcuries of alpha-emitting material.

E. Sealed sources need not be tested if they are in storage and are not being used; however, when they are removed from storage for use or transferred to another person and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

F. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. The report shall be filed within 5 days of the date the leak test result is known with the U.S. Nuclear Regulatory Commission, Region IV, 611 Ryan Plaza Drive, Suite 400, Arlington, Texas 76011, ATTN: Director, Division of Nuclear Materials Safety. The report shall specify the source involved, the test results, and corrective actions taken.

G. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or by other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.

15. The licensee shall conduct a physical inventory every six months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sources and/or devices received and possessed under the license.

16. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

NRC FORM 374A U.S. NUCLEAR REGULATORY COMMISSION

PAGE 4 of 4 PAGES

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
40-16775-01

Docket or Reference Number
030-11624

Amendment No. 19

17. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Application dated December 23, 2002
B. Letter dated June 18, 2003

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: JUN 25 2003

By: Jacqueline D. Cook

Jacqueline D. Cook, Sr. Health Physicist
Nuclear Materials Licensing Branch
Region IV
Arlington, Texas 76011

JAN - 5 2005
DATE

This is to acknowledge the receipt of your letter/application dated 12/23/04, and to inform you that the initial processing, which includes an administrative review, has been performed.

☒ There were no administrative omissions. Your application will be assigned to a technical reviewer. Please note that the technical review may identify additional omissions or require additional information. To add Dr. Pasch to license.

☐ Please provide to this office within 30 days of your receipt of this card:

The action you requested is normally processed within — days.

☐ A copy of your action has been forwarded to our License Fee & Accounts Receivable Branch, who will contact you separately if there is a fee issue involved.

Your action has been assigned **Mail Control Number** 470315.
When calling to inquire about this action, please refer to this mail control number.
You may call me at 817-860-8103.

Sincerely,

Colleen Munahan

Licensing Assistant

NRC FORM 532 (RIV)
(9-2003)

BETWEEN:

License Fee Management Branch, ARM
and
Regional Licensing Sections

(FOR LFMS USE)
INFORMATION FROM LTS

Program Code: 02120
Status Code: 2
Fee Category: 7C
Exp. Date: 20041231
Fee Comments: CODE 21
Decom Fin Assur Reqd: N

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED
   Applicant/Licensee: AVERA SACRED HEART HOSPITAL
   Received Date: 20041213
   Docket No: 3003235
   Control No.: 470315
   License No.: 40-01683-01
   Action Type: Notifications

2. FEE ATTACHED
   Amount: /
   Check No.: /

3. COMMENTS

Signed Colleen Mussehan
Date 1/5/05

B. LICENSE FEE MANAGEMENT BRANCH (Check when milestone 03 is entered /__/)

1. Fee Category and Amount: _____

2. Correct Fee Paid. Application may be processed for:
   Amendment _____
   Renewal _____
   License _____

3. OTHER _____
   _____

Signed _____
Date _____